A reduced effect of a given dose of ∆ 9 -tetrahydrocannabinol (THC) emerges with repeated exposure to the drug. This tolerance can vary depending on THC dose, exposure chronicity and the behavioral or physiological measure of interest. A novel THC inhalation system based on e-cigarette technology has been recently shown to produce the hypothermic and antinociceptive effects of THC in rats.
Introduction
Human cannabis consumers are increasingly using e-cigarette type devices filled with cannabis extracts to administer an active dose of ∆ 9 -tetrahydrocannabinol (THC) and other constuents (Mammen et al., 2016; Morean et al., 2015; Morean et al., 2017) . This has spurred interest in the development of pre-clinical models which are capable of a similar route of drug administration in laboratory rodents.
Recent studies showed that intrapulmonary delivery of THC using an e-cigarette based system results in a robust and dose-dependent hypothermia and antinociception in male and female rats (Nguyen et al., 2016b ) and a similar approach produces hypothermia in mice following inhalation exposure to synthetic cannabinoid agonists (Lefever et al., 2017) . Such systems also induce locomotor stimulation after inhalation of methamphetamine, mephedrone or 3,4-methylenedioxypyrovalerone (Nguyen et al., 2016a) and can produce escalated self-administration of sufentanil to the point of dependence (Vendruscolo et al., 2017) . These prior studies of cannabinoid inhalation focused on the acute effects of THC and did not attempt to provide any evidence of plasticity (i.e., tolerance or sensitization) of the cannabinoid-typical behavioral or physiological effects that result. It has been well established that repeated exposure to THC via parenteral injection produces tolerance to the acute effects in laboratory animals such as mice (Anderson et al., 1975; Fan et al., 1994) , rats (Jarbe, 1978; Taylor and Fennessy, 1978; Wiley and Burston, 2014) or monkeys (Ginsburg et al., 2014; Smith et al., 1983; Winsauer et al., 2011) . Thus it is of significant interest to determine if repeated exposure to THC via e-cigarette type inhalation is capable of producing tolerance in rats to further validate this model.
A substantial and sustained decrease in body temperature, and a reduction in sensitivity to a noxious stimulus (antinociception), are two major indicators of cannabinoid-like activity in laboratory rodents . These measures have been shown to be consistently affected by the inhalation of THC via e-cigarette type technology in both male and female rats (Javadi-Paydar et al., 2017; Nguyen et al., 2016b) . This study was therefore designed to determine if the body temperature response to, and antinociceptive effects of, the inhalation of THC via e-cigarette type technology are attenuated by repeated daily exposure in male or female rats. As humans increasingly ingest THC via ecigarette technology it has become increasingly important to develop translational pre-clinical models generation apparatus were selected to produce similar acute effects of THC inhlation as the first study based on pilot and other ongoing studies.
The chamber air for both apparatuses was vacuum-controlled by a chamber exhaust valve (i.e., a "pull" system) to flow room ambient air through an intake valve at ~2-3 L per minute. This functioned to ensure that vapor entered the chamber on each device-triggered event. The vapor stream was integrated with the ambient air stream once triggered. The vapor cloud cleared from the chamber by 4 minutes after the puff delivery.
Body Temperature
The body temperature was determined by rectal measurement with a lubricated thermistor (VWR Traceable™ Digital Thermometer) as previously described (Gilpin et al., 2011) .
Nociception Assay
Tail-withdrawal antinociception was assessed using a water bath (Bransonic® CPXH Ultrasonic Baths, Danbury, CT) maintained at 52°C. The latency to withdraw the tail was measured using a stopwatch, and a cutoff of 15 seconds was used to avoid any possible tissue damage (Wakley and Craft, 2011; Wakley et al, 2014) . Tail-withdrawal was assessed 35, 60 and 120 minutes after the initiation of inhalation for the first study and 35 minutes after the start of inhalation for the second study. The person performing the assay was blinded to the treatment condition for a given subject.
Plasma THC Analysis
Blood samples were collected (~500 ul) via jugular needle insertion under anesthesia with an isoflurane/oxygen vapor mixture (isoflurane 5% induction, 1-3% maintenance) 35 minutes post-initiation of vapor inhalation. Plasma THC content was quantified using fast liquid chromatography/mass spectrometry (LC/MS) adapted from (Irimia et al., 2015; Lacroix and Saussereau, 2012; Nguyen et al., 2017) . 5 μL of plasma were mixed with 50 μL of deuterated internal standard (100 ng/mL CBD-d3 and THC-d3; Cerilliant), and cannabinoids were extracted into 300 μL acetonitrile and 600 μL of chloroform and then dried. Samples were reconstituted in 100 μL of an acetonitrile/methanol/water (2:1:1) mixture.
Separation was performed on an Agilent LC1100 using an Eclipse XDB-C18 column (3.5um, 2.1mm x 100mm) using gradient elution with water and methanol, both with 0.2 % formic acid (300 μL/min; 73-90%). Cannabinoids were quantified using an Agilent MSD6140 single quadrupole using electrospray ionization and selected ion monitoring [CBD (m/z=315.2), CBD-d3 (m/z=318.3), THC (m/z=315.2) and THC-d3 (m/z=318.3)]. Calibration curves were conducted for each assay at a concentration range of 0-200 ng/mL and observed correlation coefficients were 0.999.
Data Analysis
Data (rectal temperature, tail-withdrawal latency) were analyzed with two-way Analysis of Variance (ANOVA) including repeated measures factors for the Drug treatment and Time Post-Initiation (Experiment 1 only) and a between-groups factor of Sex. Any significant main effects were followed with post-hoc analysis using the Tukey (multi-level comparisons) or Sidak (two-level comparisons)
procedures. All analysis used Prism 7 for Windows (v. 7.03; GraphPad Software, Inc, San Diego CA).
Experiments

Experiment 1 (Twice-daily THC vapor inhalation)
The initial study was conducted in groups of male (N=8; 17 weeks of age at start of this study) and female (N=8; 17 weeks of age) Wistar rats. Inhalation sessions were 30 minutes in duration with four 10 second vapor puffs delivered every 5 minutes with a 5.25 h interval between session initiations on each repeated-exposure day. The THC concentration was 200 mg/ml in this study. These animals had been initially evaluated with parenteral injection of THC (0, 10, 20, 20 mg/kg i.p.) in the stated (ascending) order with 2-3 day intervals between test days completed six weeks prior to the start of the chronic vapor inhalation experiment (not shown). For the repeated dosing, rats were exposed to vapor inhalation for 4 sequential days with twice-daily sessions (4 h interval between session initiations each day). Animals were evaluated for temperature and nociceptive responses after one PG-inhalation session ~4 weeks after repeated dosing. Temperature and antinociceptive effects of THC inhalation were assessed starting ~35 min after the start of inhalation on the first and seventh sessions.
Experiment 2 (Thrice-daily THC vapor inhalation)
The second study was conducted with groups of experimentally naive female and male rats (N=8 per group) aged 14 weeks at the start of the experiments. The main goal was to use a more intensive THC regimen to determine if that was sufficient to induce tolerance in the males, after the failure to observe tolerance in Experiment 1. Rats first received a baseline temperature / nociception assessment without any inhalation treatment. Next, rats were assessed after PG inhalation and then after the 1 st and 10 th exposures during the THC regimen of four days with thrice-daily inhalation (3 h interval between session initiations on each day). Inhalation sessions were 30 minutes in duration with 1 six second vapor puff of THC (200 mg/ml) delivered every 5 minutes.
Experiment 3 (Plasma THC levels)
This study was conducted in the second groups of male and female rats that were exposed to repeated THC three times-daily sessions in Experiment 2. Blood was withdrawn ~35 min after the start of inhalation of THC (200 mg/mL). Blood collections were conducted seven days (N= 4 per group) or 17 days (N=4 per group) after the last session of the repeated-dosing experiment.
Results
Experiment 1 (Twice-daily THC vapor inhalation)
The inhalation of THC (200 mg/mL in the PG; 30 minute exposure) reduced body temperature and increased tail-withdrawal latency in male and female rats (Figure 1) 
Experiment 2 (Thrice-daily THC inhalation)
THC inhalation decreased body temperature in both male and female groups (Figure 2) . The analysis confirmed significant effects of Sex [F (1, 14) = 10.16; P<0.01], Drug treatment condition [F (3, 42) = 394.6; P<0.0001] and the interaction of factors [F (3, 42) = 13.53; P<0.0001]. The post-hoc test confimed that temperature was significantly lower than baseline or PG temperature after each THC condition in both groups. The post-hoc test further confirmed there was a significant attenuation of the hypothermia after THC session 10 versus session 1 for each group and also a sex difference after the first and tenth THC inhalation sessions.
THC inhalation increased antinociception in both male and female groups (Figure 2) but there was a significant attenuation of this effect after repeated THC exposure. The analysis confirmed significant effect of Drug treatment condition [F (3, 42) = 62.4; P<0.0001], but not of sex or the interaction of factors. The post-hoc test confirmed that tail-withdrawal latency was higher after the first THC inhalation compared to all other treatment conditions in each group.
Experiment 3 (Pharmacokinetics)
The mean plasma levels achieved five minutes after the end of a 30 minute session of inhalation were similar for female (303 ng/mL; SEM 37.4) and male (362 ng/mL; SEM 52.5) rats with one significant outlier male contributing to the mean difference (Figure 3) .
The unpaired t-test did not confirm any differences between the groups. There were no consistent differences associated with the timing of the blood sampling experiment relative to the chronic exposure days (two-way ANOVA not significant). Thus, if there was residual THC in the animals, these levels were negligilble compared to the magnitude of the effect of the acute dosing. 
Discussion
This study is the first to show that repeated inhalation of THC vapor, using an e-cigarette based delivery system, induces tolerance to hypothermia and antinociception in both male and female rats.
Significant tolerance was observed following the 7 th session of a twice daily regimen in female rats only in the first experiment, and after the 10 th session of the t.i.d. regimen in male and female rats in the second experiment. These behavioral results were produced by an acute exposure that produces similar plasma THC leves across male and female animals, as evidenced by Figure 3 The development of tolerance to THC depends on dose, frequency of exposure and the behavioral or physiological endpoint that is under investigation. One interesting outcome of the study is that tolerance to antinociceptive and thermoregulatory effects of THC inhalation are not necessarily the same in magnitude. In both experiments the relative effect on antinociceptive responses was greater.
Thus the primary importance of these data are the demonstration that tolerance can be produced. It has been previously demonstrated that THC exposure by injection or by inhalation approximately once per week does not cause significant tolerance in rats (Borgen and Davis, 1973; Javadi-Paydar et al., 2017) .
A number of publications show, alternately, that a four to ten day regimen of once or twice daily injection of THC (Delatte et al., 2002; Kwilasz and Negus, 2012; Marusich et al., 2015; Moore et al., 2010; Wakley et al., 2014; Wiley and Burston, 2014; Winsauer et al., 2015) , or CB1 full agonists (De Vry et al., 2004) , produces tolerance on a variety of measures affected by acute THC. Likewise, tolerance to the effects of inhalation of marijuana smoke was observed after the 13 th of every other day exposure (Fried, 1976) in rats but once daily marijuana smoke exposure for two weeks (M-F) did not induce cross tolerance to the locomotor suppressive effects of the endogenous cannabinoid anandamide (Bruijnzeel et al., 2016) .
